Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
Background. The aim of this observational study is to investigate the efficacy and safety of two approved oral disease-modifying therapies (DMTs) in patients with remitting-relapsing multiple sclerosis (RRMS): dimethyl fumarate (DMF) vs. teriflunomide (TRF). Methods. A total of 159 RRMS patients (82...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Neurology Research International |
Online Access: | http://dx.doi.org/10.1155/2021/6679197 |
id |
doaj-48349cd128ee4c41bf331e50af579e51 |
---|---|
record_format |
Article |
spelling |
doaj-48349cd128ee4c41bf331e50af579e512021-07-26T00:33:59ZengHindawi LimitedNeurology Research International2090-18602021-01-01202110.1155/2021/6679197Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple SclerosisNasim Nehzat0Omid Mirmosayyeb1Mahdi Barzegar2Reza Vosoughi3Erfane Fazeli4Vahid Shaygannejad5Isfahan Neurosciences Research CenterIsfahan Neurosciences Research CenterIsfahan Neurosciences Research CenterUniversity of TorontoIsfahan Neurosciences Research CenterIsfahan Neurosciences Research CenterBackground. The aim of this observational study is to investigate the efficacy and safety of two approved oral disease-modifying therapies (DMTs) in patients with remitting-relapsing multiple sclerosis (RRMS): dimethyl fumarate (DMF) vs. teriflunomide (TRF). Methods. A total of 159 RRMS patients (82 on TRF and 77 on DMF) were included. The expanded disability status scale (EDSS), confirmed disability improvement (CDI), confirmed disability progression (CDP), and annualized relapse rate (ARR) were evaluated for the two-year period prior to enrollment in our study. The drug-associated adverse effects (AEs) were recorded. We conducted propensity matching score to compare the efficacy between TRF and DMF. Results. After matching for the confounders, TRF- and DMF-treated groups were not different in terms of EDSS (P value = 0.54), CDI (P value = 0.80), CDP (P value = 0.39), and ARR (P value >0.05). TRF discontinuation occurred in 2 patients (2.43%) due to mediastinitis and liver dysfunction, while a patient (1.29%) discontinued DMF due to depression. Incidence rate of AEs in the TRF-treated group was 81.4%: hair thinning (hair loss) (62.9%), nail loss (20.9%), and elevated aminotransferase (14.8%) were the most common AEs; in DMF-treated patients, AEs were 88.2% with predominance of flushing (73.2%), pruritus (16.9%), and abdominal pain (16.9%). Conclusion. Based on our findings, DMF is as efficacious and safe as TRF for the treatment of RRMS in our Iranian study population. Multicentric studies need to corroborate these findings in other populations.http://dx.doi.org/10.1155/2021/6679197 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nasim Nehzat Omid Mirmosayyeb Mahdi Barzegar Reza Vosoughi Erfane Fazeli Vahid Shaygannejad |
spellingShingle |
Nasim Nehzat Omid Mirmosayyeb Mahdi Barzegar Reza Vosoughi Erfane Fazeli Vahid Shaygannejad Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis Neurology Research International |
author_facet |
Nasim Nehzat Omid Mirmosayyeb Mahdi Barzegar Reza Vosoughi Erfane Fazeli Vahid Shaygannejad |
author_sort |
Nasim Nehzat |
title |
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis |
title_short |
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis |
title_full |
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis |
title_fullStr |
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis |
title_full_unstemmed |
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis |
title_sort |
comparable efficacy and safety of teriflunomide versus dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis |
publisher |
Hindawi Limited |
series |
Neurology Research International |
issn |
2090-1860 |
publishDate |
2021-01-01 |
description |
Background. The aim of this observational study is to investigate the efficacy and safety of two approved oral disease-modifying therapies (DMTs) in patients with remitting-relapsing multiple sclerosis (RRMS): dimethyl fumarate (DMF) vs. teriflunomide (TRF). Methods. A total of 159 RRMS patients (82 on TRF and 77 on DMF) were included. The expanded disability status scale (EDSS), confirmed disability improvement (CDI), confirmed disability progression (CDP), and annualized relapse rate (ARR) were evaluated for the two-year period prior to enrollment in our study. The drug-associated adverse effects (AEs) were recorded. We conducted propensity matching score to compare the efficacy between TRF and DMF. Results. After matching for the confounders, TRF- and DMF-treated groups were not different in terms of EDSS (P value = 0.54), CDI (P value = 0.80), CDP (P value = 0.39), and ARR (P value >0.05). TRF discontinuation occurred in 2 patients (2.43%) due to mediastinitis and liver dysfunction, while a patient (1.29%) discontinued DMF due to depression. Incidence rate of AEs in the TRF-treated group was 81.4%: hair thinning (hair loss) (62.9%), nail loss (20.9%), and elevated aminotransferase (14.8%) were the most common AEs; in DMF-treated patients, AEs were 88.2% with predominance of flushing (73.2%), pruritus (16.9%), and abdominal pain (16.9%). Conclusion. Based on our findings, DMF is as efficacious and safe as TRF for the treatment of RRMS in our Iranian study population. Multicentric studies need to corroborate these findings in other populations. |
url |
http://dx.doi.org/10.1155/2021/6679197 |
work_keys_str_mv |
AT nasimnehzat comparableefficacyandsafetyofteriflunomideversusdimethylfumarateforthetreatmentofrelapsingremittingmultiplesclerosis AT omidmirmosayyeb comparableefficacyandsafetyofteriflunomideversusdimethylfumarateforthetreatmentofrelapsingremittingmultiplesclerosis AT mahdibarzegar comparableefficacyandsafetyofteriflunomideversusdimethylfumarateforthetreatmentofrelapsingremittingmultiplesclerosis AT rezavosoughi comparableefficacyandsafetyofteriflunomideversusdimethylfumarateforthetreatmentofrelapsingremittingmultiplesclerosis AT erfanefazeli comparableefficacyandsafetyofteriflunomideversusdimethylfumarateforthetreatmentofrelapsingremittingmultiplesclerosis AT vahidshaygannejad comparableefficacyandsafetyofteriflunomideversusdimethylfumarateforthetreatmentofrelapsingremittingmultiplesclerosis |
_version_ |
1721282520010457088 |